Loss of UHRF2 Is Associated With Non-small Cell Lung Carcinoma Progression

被引:16
|
作者
Jin, Chun [1 ]
Xiong, Dian [2 ]
Li, Hao-Ran [1 ]
Jiang, Jia-Hao [1 ]
Qi, Jian-Chao [3 ]
Ding, Jian-Yong [1 ]
机构
[1] Fudan Univ, Affiliated Zhongshan Hosp, Dept Thorac Surg, 180 Fenglin Rd, Shanghai 200032, Peoples R China
[2] Nanchang Univ, Affiliated Hosp 2, Dept Cardiothorac Surg, Nanchang 330000, Jiangxi, Peoples R China
[3] Fujian Prov Hosp, Dept Emergency Surg, Fuzhou 350001, Fujian, Peoples R China
来源
JOURNAL OF CANCER | 2018年 / 9卷 / 17期
关键词
NSCLC; UHRF2; 5-hmC; demethylation; CYCLE NETWORK; TET ENZYMES; 5-HYDROXYMETHYLCYTOSINE; GENOME; TDG; HYPERMETHYLATION; 5-METHYLCYTOSINE; EXPRESSION; TARGET;
D O I
10.7150/jca.25876
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent evidence indicated ubiquitin like with PHD and ring finger domains 2 (UHRF2) was involved in various human diseases, especially in cancer, however, its roles in cancer are still in dispute. Here, we found UHRF2 expression was decreased in lung cancer tissues compared with adjacent normal tissues by referring to the Oncomine Database, which was further identified by immunoblotting and quantitative real-time polymerase chain reaction assays. Secondly, we found knockdown of UHRF2 in A549 and 95-D cell lines enhanced the capability of proliferation, invasion and migration, while forced UHRF2 expression inhibited NSCLC cells proliferation,invasion and migration. Mechanistically, dot-blot and western blot assays indicated that the level of UHRF2 was positively correlated with 5-hmC level by affecting ten-eleven translocation 2 (TET2) expression. Clinically, UHRF2 downregulation is significantly correlated with a malignant phenotype, including larger tumor size and poor differentiation. Moreover, UHRF2 downregulated correlates with shorter overall survival(OS). Conclusion: Our findings indicate that UHRF2 is a tumor suppressor in NSCLC by influence TET2 expression and serve as a potential therapeutic target in NSCLC.
引用
收藏
页码:2994 / 3005
页数:12
相关论文
共 50 条
  • [21] Artemin-Stimulated Progression of Human Non-Small Cell Lung Carcinoma Is Mediated by BCL2
    Tang, Jian-Zhong
    Kong, Xiang-Jun
    Kang, Jian
    Fielder, Graeme C.
    Steiner, Michael
    Perry, Jo K.
    Wu, Zheng-Sheng
    Yin, Zhinan
    Zhu, Tao
    Liu, Dong-Xu
    Lobie, Peter E.
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (06) : 1697 - 1708
  • [22] Early stage non-small cell Lung carcinoma
    Eberhardt, Wilfried
    Griesinger, Frank
    Filipits, Martin
    Winter, Hauke
    ONKOLOGIE, 2012, 35 : 6 - 9
  • [23] CHEMOTHERAPY OF NON-SMALL CELL-CARCINOMA OF LUNG
    TATTERSALL, MHN
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1978, 8 (04): : 451 - 452
  • [24] THE PATHOLOGY OF NON-SMALL CELL-CARCINOMA OF THE LUNG
    MATTHEWS, MJ
    MACKAY, B
    LUKEMAN, J
    SEMINARS IN ONCOLOGY, 1983, 10 (01) : 34 - 55
  • [25] Predictive immunocytochemistry in non-small cell lung carcinoma
    Brcic, Luka
    Prince, Spasenija Savic
    PATHOLOGIE, 2022, 43 (03): : 222 - 228
  • [26] Predictive immunocytochemistry in non-small cell lung carcinoma
    Brcic, Luka
    Prince, Spasenija Savic
    PATHOLOGE, 2022, 43 (03): : 222 - 228
  • [27] KRAS Amplification in Non-Small Cell Lung Carcinoma
    Stiedl, A. C.
    Wagner, P. L.
    Wilbertz, T.
    Altorki, N. K.
    Perner, S. R.
    LABORATORY INVESTIGATION, 2010, 90 : 414A - 414A
  • [28] Targeted Therapy in non-small cell Lung Carcinoma
    Tessmer, Antje
    Kollmeier, Jens
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (05) : 324 - 330
  • [29] Palliative radiotherapy for non-small cell lung carcinoma
    Powell, J.
    Davies, S.
    Lester, J. F.
    Button, M. R.
    Brewster, A. E.
    Hanna, L.
    LUNG CANCER, 2010, 67 : S30 - S30
  • [30] Genetic changes in non-small cell lung carcinoma
    Uvirova, M.
    Urbanovska, I.
    Konvalinka, D.
    Simova, J.
    Kubova, B.
    Jaluvkova, M.
    Zmolikova, J.
    Ziak, D.
    Dvorackova, J.
    VIRCHOWS ARCHIV, 2012, 461 : S172 - S172